OBJECTIVE: Unlike other histological types of epithelial ovarian carcinoma, ovarian clear cell carcinoma is known to have very poor response to therapy even when discovered in its early stages. Since tumor hypoxia has been shown to be strongly associated with poor prognosis, deregulation of the representative factor of tissue hypoxia; hypoxia-inducible factor 1 alpha (HIF-1alpha) and related protein; Von Hippel-Lindau (VHL) may be associated with poor prognosis of ovarian clear cell carcinoma. METHODS: Immunolocalization of both HIF-1alpha and VHL was performed on 56 cases of paraffin-embedded tissue sections of four different histological types of epithelial ovarian carcinoma and 5 cases of benign ovarian tumors as a control. Quantitative RT-PCR analysis of both HIF1A and VHL was performed on RNA isolated from 61 microdissected frozen tissues of four different histological types of epithelial ovarian carcinoma and 6 cases of normal ovarian epithelial cells. Expression levels of HIF-1alpha and VHL in different histological types and correlation between HIF-1alpha and VHL were determined by nonparametric analysis by Kruskal-Wallis and Spearman's test. RESULTS: HIF-1alpha expression levels were significantly higher in ovarian clear cell carcinoma than in other histological types (P=0.001). We found no correlation between mRNA and protein expression level in any type of carcinoma specimens. Among endometrioid, serous, and mucinous carcinoma, there were no differences in HIF-1alpha expression (P=0.643). There was a negative correlation between HIF-1alpha and VHL in serous (r=-0.661, P=0.027) and in endometrioid carcinoma (r=-0.657 P=0.039), but no correlation was found between HIF-1alpha and VHL expression levels in ovarian clear cell carcinoma (P=0.60). CONCLUSIONS: The results suggest that the role of hypoxia may change according to the histological type of ovarian carcinoma. High expression of HIF-1alpha and its independence from VHL in ovarian clear cell carcinoma may confer chemoresistance in this histological type.
OBJECTIVE: Unlike other histological types of epithelial ovarian carcinoma, ovarian clear cell carcinoma is known to have very poor response to therapy even when discovered in its early stages. Since tumor hypoxia has been shown to be strongly associated with poor prognosis, deregulation of the representative factor of tissue hypoxia; hypoxia-inducible factor 1 alpha (HIF-1alpha) and related protein; Von Hippel-Lindau (VHL) may be associated with poor prognosis of ovarian clear cell carcinoma. METHODS: Immunolocalization of both HIF-1alpha and VHL was performed on 56 cases of paraffin-embedded tissue sections of four different histological types of epithelial ovarian carcinoma and 5 cases of benign ovarian tumors as a control. Quantitative RT-PCR analysis of both HIF1A and VHL was performed on RNA isolated from 61 microdissected frozen tissues of four different histological types of epithelial ovarian carcinoma and 6 cases of normal ovarian epithelial cells. Expression levels of HIF-1alpha and VHL in different histological types and correlation between HIF-1alpha and VHL were determined by nonparametric analysis by Kruskal-Wallis and Spearman's test. RESULTS:HIF-1alpha expression levels were significantly higher in ovarian clear cell carcinoma than in other histological types (P=0.001). We found no correlation between mRNA and protein expression level in any type of carcinoma specimens. Among endometrioid, serous, and mucinous carcinoma, there were no differences in HIF-1alpha expression (P=0.643). There was a negative correlation between HIF-1alpha and VHL in serous (r=-0.661, P=0.027) and in endometrioid carcinoma (r=-0.657 P=0.039), but no correlation was found between HIF-1alpha and VHL expression levels in ovarian clear cell carcinoma (P=0.60). CONCLUSIONS: The results suggest that the role of hypoxia may change according to the histological type of ovarian carcinoma. High expression of HIF-1alpha and its independence from VHL in ovarian clear cell carcinoma may confer chemoresistance in this histological type.
Authors: Nurith Kurn; Pengchin Chen; Joe Don Heath; Anne Kopf-Sill; Kathryn M Stephens; Shenglong Wang Journal: Clin Chem Date: 2005-08-25 Impact factor: 8.327
Authors: B A Goff; R Sainz de la Cuesta; H G Muntz; D Fleischhacker; M Ek; L W Rice; N Nikrui; H K Tamimi; J M Cain; B E Greer; A F Fuller Journal: Gynecol Oncol Date: 1996-03 Impact factor: 5.482
Authors: P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe Journal: Nature Date: 1999-05-20 Impact factor: 49.962
Authors: P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe Journal: Science Date: 2001-04-05 Impact factor: 47.728
Authors: M I Koukourakis; A Giatromanolaki; J Skarlatos; L Corti; S Blandamura; M Piazza; K C Gatter; A L Harris Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam Journal: Mol Imaging Date: 2011-04-26 Impact factor: 4.488
Authors: Parvin Ataie-Kachoie; Mohammad H Pourgholami; Farnaz Bahrami-B; Samina Badar; David L Morris Journal: Am J Cancer Res Date: 2015-01-15 Impact factor: 6.166
Authors: Colles Price; Stanley Gill; Zandra V Ho; Shawn M Davidson; Erin Merkel; James M McFarland; Lisa Leung; Andrew Tang; Maria Kost-Alimova; Aviad Tsherniak; Oliver Jonas; Francisca Vazquez; William C Hahn Journal: Cancer Res Date: 2019-03-21 Impact factor: 12.701
Authors: William M Merritt; Christopher G Danes; Mian M K Shahzad; Yvonne G Lin; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Lingegowda S Mangala; Rebecca L Stone; Hye Sun Kim; David M Gershenson; Robert B Jaffe; Robert L Coleman; Joya Chandra; Anil K Sood Journal: Cancer Biol Ther Date: 2009-08-13 Impact factor: 4.742